The Yale Cancer Center is committed to ensuring the safety of patients participating in clinical trials and requires all clinical trials conducted at the YCC to include provisions for data and safety monitoring. The development of protocol monitoring plans and reporting requirements are dependent upon the overall risk to patients, the nature of the agent, the phase of the trial and prior safety data with the proposed treatment regimen, the role of the Yale principal investigator and the institution, and the study sponsor. The original NCI approved Yale Cancer Center (YCC) Data and Safety Monitoring Plan was recently revised and approved by NCI in July of 2011. The plan outlines the scope of protocol oversight which is operationalized by the YCC Data and Safety Monitoring Committee (DSMC). While each investigator is responsible for the day to day monitoring of a study, the initial scientific review conducted by the YCC Protocol Review Committee (PRC) includes the assignment of a more detailed protocol specific plan requiring additional oversight provided by the DSMC. For studies without external monitoring this includes a protocol specific schedule for safety review and internal auditing. The Office of Protocol Review and Monitoring (OPRM), headed by Susan Anderson, is the administrative arm of the DSMC. 12.2 PURPOSE OF THE DSMC

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-34
Application #
8558333
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-01
Project End
2018-07-31
Budget Start
2013-09-09
Budget End
2014-07-31
Support Year
34
Fiscal Year
2013
Total Cost
$67,393
Indirect Cost
$26,917
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ols, Michelle L; Cullen, Jaime L; Turqueti-Neves, Adriana et al. (2016) Dendritic Cells Regulate Extrafollicular Autoreactive B Cells via T Cells Expressing Fas and Fas Ligand. Immunity 45:1052-1065
Gale, Molly; Sayegh, Joyce; Cao, Jian et al. (2016) Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget 7:39931-39944
Ducker, Gregory S; Chen, Li; Morscher, Raphael J et al. (2016) Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab 23:1140-53
Adams, Brian D; Wali, Vikram B; Cheng, Christopher J et al. (2016) miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Res 76:927-39
Santin, Alessandro D; Bellone, Stefania; Buza, Natalia et al. (2016) Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res 22:5682-5687
de Haydu, Christopher; Black, Jonathan D; Schwab, Carlton L et al. (2016) An update on the current pharmacotherapy for endometrial cancer. Expert Opin Pharmacother 17:489-99
Hollander, Lindsay; Guo, Xiaojia; Velazquez, Heino et al. (2016) Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Cancer Res 76:3884-94
Zhao, Siming; Bellone, Stefania; Lopez, Salvatore et al. (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 113:12238-12243
Park, Sin-Aye; Lee, Jong Woo; Herbst, Roy S et al. (2016) GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer. PLoS One 11:e0153075
Stein, Stacey M; James, Edward S; Deng, Yanhong et al. (2016) Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 114:737-43

Showing the most recent 10 out of 275 publications